http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 29 May 2026 07:40:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html si-local-file:///var/storage/secattach/20260529/26570799.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html Fri, 29 May 2026 07:40:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html si-local-file:///var/storage/secattach/20260529/26570799.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html Fri, 29 May 2026 07:40:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html si-local-file:///var/storage/secattach/20260529/26570799.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+29/26570799.html Fri, 29 May 2026 07:40:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html <p align="justify">SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been further delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target http://www.streetinsider.com/Globe+Newswire/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26570765.html Fri, 29 May 2026 07:30:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html si-local-file:///var/storage/secattach/20260513/26487511.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html Wed, 13 May 2026 17:16:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html si-local-file:///var/storage/secattach/20260513/26487511.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html Wed, 13 May 2026 17:16:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html si-local-file:///var/storage/secattach/20260513/26487511.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Aptose+Biosciences+Inc.+++For%3A+Mar+31/26487511.html Wed, 13 May 2026 17:16:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html si-local-file:///var/storage/secattach/20260513/26487506.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html Wed, 13 May 2026 17:15:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html si-local-file:///var/storage/secattach/20260513/26487506.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html Wed, 13 May 2026 17:15:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html si-local-file:///var/storage/secattach/20260513/26487506.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+May+13/26487506.html Wed, 13 May 2026 17:15:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Press+Releases/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html <p align="justify">SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.   </p> <p align="justify">“Our TUSCANY clinical trial of tuspetinib in combination with venetoclax (VEN) and azacitidine (AZA) for frontline treatment of newly diagnosed acute myeloid leukemia (AML) continues to deliver robust safety and response data, http://www.streetinsider.com/Globe+Newswire/Aptose+Reports+First+Quarter+2026+Results%C2%A0/26487256.html Wed, 13 May 2026 17:00:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html si-local-file:///var/storage/secattach/20260430/26400715.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html Thu, 30 Apr 2026 07:35:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html si-local-file:///var/storage/secattach/20260430/26400715.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html Thu, 30 Apr 2026 07:35:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html si-local-file:///var/storage/secattach/20260430/26400715.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Aptose+Biosciences+Inc.+++For%3A+Apr+30/26400715.html Thu, 30 Apr 2026 07:35:00 -0400 APS APTOF O.00674004 http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26400644.html <p align="justify">SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“<strong>Aptose</strong>” or the “<strong>Company</strong>”) (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement (the “Arrangement”) with Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“Hanmi Purchaser” and together with Hanmi, the “Hanmi Purchasers”), has been delayed as certain Korean regulatory approvals pertaining to the Arrangement remain in progress. The parties do not anticipate that the review will prevent closing and continue to work toward completing the Arrangement that they now target for http://www.streetinsider.com/Press+Releases/Aptose+Biosciences+Announces+Update+on+Anticipated+Timing+of+Closing+of+the+Plan+of+Arrangement+with+Hanmi+Pharmaceutical/26400644.html Thu, 30 Apr 2026 07:30:00 -0400 APS APTOF O.00674004